Please login to the form below

Not currently logged in
Email:
Password:

Editas Medicine names James Mullen as chairman

He has previously served as CEO of Patheon

Jim MullenGenome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.

Mullen has over 30 years’ experience leading biotechnology and pharmaceutical organisations on a global scale.

Previously, Mullen has served as chief executive officer of Patheon, a pharmaceutical development and manufacturing services provider, until its acquisition by Thermo Fisher Scientific last year.

Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.

Katrine Bosley, president and chief executive officer of Editas Medicine, said: “Jim is a renowned leader in the biotechnology industry with deep experience building global companies and guiding corporate strategy, and I am very pleased to welcome his as chairman of the board.

“Jim’s extensive experience in driving excellence across R&D, commercialisation, manufacturing, business development and capital formation will be invaluable as we continue to build a genomic medicine leader and develop medicines for patients in the years to come.”

In addition, the company announced that Alexis Borisy and John Mendlein stepped down from the board.

12th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics